Biosimilar MW032 Vs Denosumab for Solid Tumor–Related Bone Metastases
1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the MW032 group and ...
1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the MW032 group and ...
1. Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab use are associated with reduced clinical fractures in postmenopausal patients with osteoporosis. 2. ...
Click to read this study in JAMA Oncology.
1. Delayed subsequent denosumab doses were shown to increase the risk for vertebral fractures compared to on-time injection. 2. There ...
1. Bisphosphonates and denosumab increased bone mineral density (BMD) in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, ...
1. This systematic review demonstrated that in postmenopausal women with osteoporosis, bisphosphonates, denosumab and teriparatide were associated with a significantly ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.